Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 6/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421178 | 0.87 | HDAC6 (0.47) | SLC6A1SLC6A11HDAC6SMN1; SMN2HDAC1 | |
| SCHEMBL14315813 | 0.86 | ALDH1A1 (0.50) | MTNR1AHDAC6SMN1; SMN2 | |
| SCHEMBL3689628 | 0.86 | TGM2 (0.45) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL3691998 | 0.86 | TGM2 (0.45) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL524569 | 0.84 | SLC6A11 (0.47) | NPC1RAB9ASLC6A1SLC6A11SMN1; SMN2 | |
| SCHEMBL3695475 | 0.83 | SLC6A11 (0.43) | SLC6A1SLC6A11KIF11 | |
| SCHEMBL3698291 | 0.83 | SLC6A11 (0.43) | SLC6A1SLC6A11KIF11 | |
| SCHEMBL5069300 | 0.83 | L3MBTL1 (0.44) | MTNR1BMTNR1AL3MBTL1HDAC6 | |
| SCHEMBL7642842 | 0.83 | CPB1 (0.47) | — | |
| SCHEMBL3689536 | 0.82 | KIF11 (0.50) | SLC6A1SLC6A11KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081949-B1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | GE HEALTHCARE DHARMACON INC (US) | 2014-12-10 | — | — | EP | disclosed |
| US-8809514-B2 | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference | GE HEALTHCARE DHARMACON, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809514-B2 | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference | GE HEALTHCARE DHARMACON, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809514-B2 | Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference | GE HEALTHCARE DHARMACON, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8501706-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501706-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501706-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2064223-B1 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | DHARMACON, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | DHARMACON, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-8252755-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252755-B2 | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference | DHARMACON, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2064223-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | Dharmacon, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | DHARMACON, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | DHARMACON, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | DHARMACON, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| WO-2008036825-A2 | DUPLEX OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | DHARMACON, INC. (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093085-A1 | TRIPARTITE OLIGONUCLEOTIDE COMPLEXES AND METHODS FOR GENE SILENCING BY RNA INTERFERENCE | SNRPE, DCLRE1B, RNASE1 | MTNR1B 3153/4885MTNR1A 3032/4885L3MBTL1 4/4885 |
| US-20120322855-A1 | Duplex Oligonucleotide Complexes and Methods for Gene Silencing by RNA Interference | SNRPE, AGO2, DCLRE1B | MTNR1B 2471/4885MTNR1A 3031/4885L3MBTL1 43/4885 |
| US-20080085869-A1 | Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism | SRRT, SNRPE, SSBP1 | MTNR1B 3913/4885MTNR1A 3887/4885L3MBTL1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.